DVALL: A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (TACL protocol T2009-003)


Leukemias / Lymphomas : Relapsed ALL


This is a pilot study to characterize side effects and feasibility of adding two new drugs (decitabine and vorinostat) in combination before and during administration of commonly used re-induction chemotherapy drugs for treating children with relapsed acute lymphocytic leukemia. There are also secondary research objectives to study the biological activity and genetic profile of these drugs. Bone marrow and blood will be collected for these studies at specified times in the protocol.


Eligibility Criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Sima Jeha, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.